Respiratory outcomes and atopy in school-age children who were preterm at birth, with and without bronchopulmonary dysplasia by Guimarães, Hercília et al.
CLINICAL SCIENCE
Respiratory outcomes and atopy in school-age
children who were preterm at birth, with and
without bronchopulmonary dysplasia
Hercı ´lia Guimara ˜es,
I,II Gustavo Rocha,
I Susana Pissarra,





IHospital de Sa ˜o Joa ˜o - Servic ¸o de Neonatologia, Porto, Portugal.
IIFaculdade de Medicina do Porto, Porto, Portugal.
IIIHospital de Sa ˜o Joa ˜o - Servic ¸ode
Pediatria, Porto, Portugal.
OBJECTIVE: To assess pulmonary function and the prevalence of atopy in school-age children who were very low
birth weight as infants and to compare those who had bronchopulmonary dysplasia to those who did not.
METHOD: We studied 85 (39 male and 46 female) at a mean age of 84 (range, 62 to 107) months who were very low
birth weight infants. Bronchopulmonary dysplasia was defined as oxygen dependency at 36 weeks gestational age.
We excluded 8 patients (4 for cerebral palsy and 4 for no collaboration). Detailed perinatal and clinical data were
collected. Lung function was evaluated using conventional spirometry. Atopy (assessed by the allergy skin-prick test)
was considered when at least one positive skin test occurred in a panel of the most common environmental
allergens in the local region. Comparisons between the bronchopulmonary dysplasia and no bronchopulmonary
dysplasia groups were performed using the Mann-Whitney, x2 and Fisher’s exact tests.
RESULTS: We compared the bronchopulmonary dysplasia (n=13) and no bronchopulmonary dysplasia (n=64)
groups. Atopy was observed in 4 (30.8%) of the bronchopulmonary dysplasia patients and in 17 (26.6%) of the no
bronchopulmonary dysplasia patients (p=0.742). Two (15.4%) patients with bronchopulmonary dysplasia had a
family history of atopy vs. 17 (26.6%) in the no bronchopulmonary dysplasia group (p=0.5). Lung function tests
showed airway obstruction in 2 (15.4%) of the bronchopulmonary dysplasia patients and in 10 (15.6%) of the no
bronchopulmonary dysplasia patients (p=1.0). Four (33.3%) of the bronchopulmonary dysplasia patients had small
airway obstruction vs. 14 (22.2%) of the no bronchopulmonary dysplasia patients (p=0.466).
CONCLUSION: Our data showed no significant differences in lung function between bronchopulmonary dysplasia
and no bronchopulmonary dysplasia patients at school age and no evidence of an association between atopy and
bronchopulmonary dysplasia.
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INTRODUCTION
Bronchopulmonary dysplasia (BPD) is a multifactorial,
chronic respiratory disease that develops as a consequence
of perinatal/neonatal lung injury. It is one of the most
important sequelae of premature birth, and its prevalence
varies widely.
1-9 In spite of receiving multifaceted treatment,
affected infants can remain oxygen dependent for many
months.
10,11 The gains in therapeutically reducing BPD have
been modest.
9,12,13 Infants who require supplementary
oxygen at home have increased healthcare utilization, even
during preschool years, when they are no longer oxygen-
dependent. Recurrent respiratory symptoms that require
treatment are common in children who were born prema-
turely, especially those who had BPD.
More than 50% of BPD patients require rehospitalization
in the first two years of life.
14 Premature children, especially
those who had BPD, are more likely to suffer frequent,
troublesome symptoms at school age and in adolescence
than term-born controls.
11,15 Studies examining adolescents
and adults have usually reported on patients who had
‘‘classical’’ BPD; that is, they often had had severe respira-
tory failure in the neonatal period with chronic pulmonary
fibrosis and airway smooth muscle hypertrophy.
6,16,17
In recent years, infants have been described as having
’’new’’ BPD, which involves developing chronic oxygen
dependence despite initially minimal or even absent
respiratory distress. However, affected patients have
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425reduced alveolarization and experience deterioration in
lung function over the first year after birth. It is essential
to determine if these patients’ lung function can ’’catch up’’
and to identify which strategies impair and, most impor-
tantly, promote lung growth in this high-risk population.
8,18
The most severely affected patients may remain sympto-
matic and have evidence of airway obstruction even as
adults. Although lung function improves over time,
abnormalities can be detected even in young adults who
had severe BPD as infants.
14,19
Because some children with BPD have recurrent wheez-
ing, the question of whether there is a correlation between
BPD and atopy arises. A family history of atopy is related to
respiratory morbidity, and an atopic predisposition was
found to be associated with the persistence of wheezing in
preterm infants.
20, 21
Nevertheless, recent studies suggest that children with
BPD do not have an increased prevalence of atopy, as do
those with asthma.
20,22
The aim of this study was to assess the pulmonary
function and prevalence of atopy in school-age children
who were less than 1500 g (VLBW) as infants and to




We studied 85 children (39 male and 46 female) at a mean
age of 84 (range, 62 to 107) months who were VLBW infants.
The children were born between January 1, 2002 and
December 31, 2004. The total number of VLBW infants in
our NICU over this period was 126. We excluded 8 (5 male
and 3 female) patients (4 for cerebral palsy and 4 for no
collaboration). All the children had been treated at our
neonatal intensive care unit. Detailed perinatal and neonatal
clinical data were collected, including the following:
treatment with prenatal steroids, intrauterine growth
restriction, gestational age at birth (GA), birth weight
(BW), hyaline membrane disease, mechanical ventilation
(MV), length of MV, oxygen therapy and length of oxygen
therapy.
The diagnosis of PBD was based on dependence on
supplementary oxygen at 36 weeks gestational age. We
classified BPD as moderate or severe according to the
consensus definition of the National Institutes of Health.
5
Follow-up at school age
A questionnaire that included questions about personal
history of allergic diseases, family history of atopy, past
respiratory symptoms, frequency of airway infections and
hospital respiratory readmissions during the previous year,
medical treatments and school absenteeism was created and
distributed.
A physical examination was conducted that included
measurements of body weight and height. To evaluate the
child’s nutritional status, we calculated the body mass index
(BMI) using charts from the National Institute of Child
Health and Human Development.
An allergy skin-prick test and spirometry were conducted
at the outpatient department.
None of the children had respiratory infections at the time
of the lung function tests. If the child was receiving
bronchodilator treatment due wheezing episodes, the
bronchodilators were withdrawn 12 hours before the
evaluation of pulmonary function.
Lung function was evaluated using conventional spiro-
metry (Compact Vitalograph, Buchingham, U.K.). At least
three acceptable flow-volume curves were obtained, follow-
ing the reproducibility criteria of the European Respiratory
Society.
23
The forced vital capacity (FVC), forced expiratory volume
at one second (FEV1), FEV1/FVC ratio (FEV%) and mid-
expiratory flow at 25 to 75% of FVC (FEF 25-75%) were
recorded. The values of Polgar were used as reference
data.
24
We defined airway obstruction and small airway obstruc-
tion as, respectively, maximal FEV1 and FEF 25-75% values
of less than 80% of the predicted values in both determina-
tions.
Atopy was assessed by the allergy skin-prick test for the
most common environmental allergens in the local region:
Dermatophagoides farinae, Dermatophagoides pteronyssi-
nus, Lepidoglyphus destructor, dog, cat, Alternaria, grami-
neae, trees, egg white, fish and peanut. Histamine chloride
(10 mg/ml) was the positive control and NaCl 0.9% was the
negative control.
Atopy was defined as at least one positive skin-prick test
(a weal with a diameter greater than or equal to the negative
control).
The parents were fully informed of the purpose of the
study and written informed consent was obtained. The
study was approved by the local ethics committee (Hospital
de Sa ˜o Joa ˜o).
Data Analysis
The BPD and no BDP groups were compared using the
Mann-Whitney, x2 and Fisher’s exact tests.
RESULTS
Perinatal and neonatal data
Out of 77 children, 25 (32.5%) were extremely low birth
weight infants.
Thirteen had BPD, of whom 12 were graded as moderate
and 1 as severe BPD. The perinatal data are presented in
Table I. The average BW and GA of the children with BPD
were significantly lower than those of the children without
BPD. The BPD risk factors were male gender, hyaline
membrane disease, length of mechanical ventilation and
oxygen therapy (Table I).
Health status and symptoms at school age
As shown in Table II, the children were observed at a
mean age of 84 (range, 62 to 107) months in the BDP group
and 92 (range, 69 to 105) months in the no BPD group
(p=0.115).
- Body mass index. In the school-age evaluation, there
was no difference between the body mass indices of the
children with and without BPD (Table II).
- Respiratory Outcomes. Wheezing was reported in 8
(61.5%) of the BPD patients and in 46 (71.9%) of the children
without BPD (p=0.063). Dyspnea was observed in 9 (69.2%)
of the children with BPD and 55 (85.9%) of those without
BPD (p=0.092).
School absenteeism was reported in 5 (6.5%) and hospital
admissions in 16 (20.7%) of our patients, and 22 (28.5%)
needed medical treatment in the first two years of life, but
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groups (Table II). In the school-age evaluation, none of
the children were on systemic steroids, and 7 (9.9%) of
them intermittently needed inhaled bronchodilators and/or
steroids.
Lung function tests (spirometry)
The majority of the children (74/77) performed the
spirometry test without difficulty. Out of 77 children, 12
had airway obstruction; of these, 6 had moderate to severe
airway obstruction.
No significant differences were seen in FVC, FEV1, FEV%
and FEF 25-75% between the BPD and no BPD patients
(Table III).
The lung function tests showed airway obstruction in 2
(15.4%) of the BPD patients and in 10 (15.6%) of the no-BPD
patients (p=1.0); 4 (33.3%) of the patients in the BPD group
had small airway obstruction, versus 14 (22.2%) in the no-
BPD group (p=0.466) (Table III).
Atopy
Atopy was observed in 4 (30.8%) of the BPD patients and
in 17 (26.6%) of the no BPD patients (p=0.742); 2 (15.4%) of
the patients in the BPD group had a family history of atopy
versus 17 (26.6%) in the no BPD group (p=0.5) (Table III).
Of the 19 patients with a familiar history of atopy, 6 (32%)
had positive skin-prick tests. Of the 21 children with
allergies, 15 (71%) did not have a family history of atopy.
DISCUSSION
In this study, we did not find significant differences in
lung function tests and atopy prevalence of school-age
children who were VLBW infants, with and without BPD.
In spite of the increased morbidity during first years of
life, our patients showed good respiratory outcomes by the
time they were school age, a finding which has also been
observed by others.
15,22,25
Some controversy still exists over the relationship
between prematurity, atopy and bronchopulmonary dys-
plasia, some aspects of which are discussed later in this
article .
20,21,24,26-29,32 Also, the prevalence of atopy at school
Table I - Clinical characteristics of the studied population
and comparisons between patients who did and did not
have BPD.
BPD (n=13) No-BPD (n=64) p
Birth weight (grams,)
median (range)
850 (565-1400) 1210 (655-1500) 0.01
X ¡ SD 900 ¡ 221 1162 ¡ 875
Gestational age (weeks),
median (range)
27 (23-30) 30 (26-35) ,0.0001
X ¡ SD 27 ¡ 1.9 29.9 ¡ 2.4
Male sex, n (%) 10 (76.9) 24 (37.5) 0.013
Intrauterine growth
restriction, n (%)
2 (15.4) 12 (18.2) 1.0
Prenatal corticosteroids,
n (%)
12 (92.3) 60 (93.8) 1.0
Hyaline membrane disease,
n (%)
13 (100) 35 (54.7) 0.01
Mechanical ventilation,
n (%)
13 (100) 55 (85.9) 0.343
MV length (days),
median (range)
58 (7-107) 10 (0-72) ,0.0001
X ¡ SD 54.5 ¡ 26.6 15.72 ¡ 16.6
Oxygen therapy, n (%) 13 (100) 50 (78.1) 0.110
Oxygen therapy length
(days), median (range)
53 (7-365) 5.5 (0-58) ,0.0001
X ¡ SD 106.3 ¡ 117.2 12.6 ¡ 15.4
X ¡ SD = mean ¡ standard deviation
Table II - Comparisons of body mass index, respiratory
symptoms, school absenteeism, hospital admissions and
treatment at school age between patients who had BPD
or did not have BPD.
BPD (n=13) No BPD (n=64) p
Age (months), median
(range)
84 (62-107) 92 (69-105) 0.115
X ¡ SD 91.0 ¡ 11.3 84.7 ¡ 13.2
Body mass index
(percentile)
, 5 1 (7.7) 4 (6.3) 0.975
5-25 4 (30.8) 17 (26.6)
25-50 5 (38.5) 30 (46.9)
50-85 2 (15.4) 7 (10.6)
. 85 1 (7.7) 6 (9.4)
Wheezing* 0.063
No wheezing, n (%) 8 (61.5) 46 (71.9)
Wheezing, n (%) 5 (38.5) 18 (28.1)
Mild, n (%) 1 (7.7) 10 (15.6)
Moderate, n (%) 1 (7.7) 6 (9.4)
Severe, n (%) 3 (23.1) 2 (3.1)
Dyspnea* 0.092
No dyspnea, n (%) 9 (69.2%) 55 (85.9)
Dyspnea, n (%) 4 (30.8) 9 (14.1)
Mild, n (%) 1 (7.7) 5 (7.8)
Moderate , n (%) 2 (15.4) 4 (6.3)
Severe, n (%) 1 (7.7) 0 (0)
Absenteeism, n (%) 1 (7.7) 4 (6.3) 1.0
Hospital respiratory
admissions, n (%)
4 (30.8) 12 (18.8) 0.452
Medical treatment, n (%) 5 (38.5) 17 (26.5) 0.50
X ¡ SD=mean ¡ standard deviation
*Definitions of severity from GINA (Global Initiative for Asthma, WHO
2008)
Table III - Atopy and lung function comparison at school
age between patients who had BPD or did not have BPD.
BPD (n=13) No-BPD (n=64) p
Age (months), median
(range)
84 (62-107) 92 (69-105) 0.115
X ¡ SD 91.0 ¡ 11.3 84.7 ¡ 13.2
Allergy (positive skin-prick
test), n (%)
4 (30.8) 17 (26.6) 0.742
Family atopy history, n (%) 2 (15.4) 17 (26.6) 0.5
Lung function
Airway obstruction, n (%) 2 (15.4) 10 (15.6) 1.0
Small airway obstruction,
n (%)
4 (33.3) 14 (22.2) 0.466
FVC, median (extremes) (%
predict)
88 (58-111) 91 (56-117) 0.157
FEV1, median (extremes)
(% predict)
79 (58-98) 89 (48-124) 0.172
FEV %, median (extremes)
(% predict)
8.5 (1-17) 6 (1-43) 0.324
FEF 25-75 %, median
(range)
(% predict) 87 (48-148) 97 (5-223) 0.439
X ¡ SD = mean ¡ standard deviation
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of the general Portuguese school-age population.
33,34
Perinatal and neonatal data
The following BPD risk factors were identified in our
patients: birth weight, gestational age at birth , male gender,
hyaline membrane disease, length of MV and length of
oxygen therapy (Table I). We expected these results based
on the findings of other authors.
6,16 No significant difference
was seen in prenatal corticosteroid treatment (Table I).
Health status and symptoms at school age
The children were observed at school age: a mean age of
84 (range, 62 to 107) months in the BDP group and a mean
age of 92 (range, 69 to 105) months in the no BPD group
(p=0.11) (Table II).
Out of 77 children, 13 had BPD; of these, only one had
severe BPD.
- Body Mass Index. In spite of some evidence that BPD
patients have increased morbidity, we did not find a
significant difference in the body mass indices of the
children with and without BPD (Table II). Our results are
consistent with a recent study in which no significant
differences were seen in weight or height at the time of
evaluation.
22 This finding may be due to most of our
children having had moderate BPD. Only one patient had
severe BPD. Another reason might be that the BPD patients
in our neonatal intensive care unit received a nutritional
protocol with a high-calorie diet.
It has been demonstrated that greater linear growth, lean
mass and bone mass occur in the enriched formula group,
which suggests that infants with bronchopulmonary dys-
plasia achieve faster ‘‘catch-up’’ growth when fed higher
intakes of protein, calcium, phosphorus, and zinc than are
provided in standard proprietary formulas.
30 Korhonen and
co-workers have shown that at 7 years of age, VLBW
children are shorter than term controls independently of
whether they had had BPD.
31
- Respiratory Outcome. Wheezing was reported in 8
(61.5%) of the BPD patients and in 46 (71.9%) of the children
without BPD (p=0.063). Dyspnea was observed in 9 (69.2%)
of the children with BPD and 55 (85.9%) of those without
BPD (p=0.092).
School absenteeism was reported in 5 (6.5%) and hospital
admissions in 16 (20.7%) of our patients, and 22 (28.5%)
needed medical treatment in the first years of life; no
significant differences were observed between the groups,
however (Table II). The BPD patients had more read-
missions in the first years of life (30.8% vs. 18.8%), as has
been shown by others.
11,19
Longitudinal studies on children with BPD have identi-
fied significant airflow obstruction and a greater need for
inhaled asthma medication at all ages.
8,19 None of the
children in the study were on systemic steroids, and about
10% of them needed intermittently inhaled bronchodilators
and/or steroids at school age.
Lung Function - Spirometry
The majority of the children performed the spirometry
test without difficulty. Lung function values from a long-
itudinal study of healthy children and adolescents have
been published by Hibbert and co-workers.
35 Our patients
were younger, however, and we used the values from our
Department of Pediatrics as references.
24
The lung function tests showed airway obstruction in
15.4% of the BPD patients, a frequency not significantly
different from the 15.6% observed in the no-BPD patients
(Table III). Out of 77 children, 12 had airway obstruction; of
these, 6 had moderate to severe airways obstruction.
Our study was not designed to evaluate whether the non-
BPD preterm group differed from healthy children born at
term. We only compared BPD and no-BPD VLBW children,
and we did not find a significant difference.
Other studies have demonstrated early impairment of
lung function at school age in BPD children,
22,36-41 and
isolated prematurity has been shown to play an important
role in children’s respiratory pathology (the role being the
impairment of lung function present in these children since
the first years of life).
15,42 Depending on its severity,
children with BPD may have reduced lung function through
childhood and into early life.
11,14,19,43
We speculate that our lung function results for PBD and
no BPD VLBW infants can be explained by the following
reasons. First, only 25 (32.5%) were extremely low birth
weight infants, and preterm children of extremely low
gestational age show greater impairment in lung function
due to reduced alveolarization.
6,18 Second, most of our
patients had moderate BPD, and only one child had severe
BPD. Severe cases show the greatest impairment in lung
function.
22
Third, the four patients who were the most severely
neurologically handicapped were excluded, along with four
others who did not choose to collaborate. These patients did
not have respiratory symptoms and had radiologically
normal lungs. Eight of the children selected for this study
could not collaborate. Nevertheless, this is not a valid reason
because they had not had BPD. Fourth, our patients had
good nutrition status, as evaluated by BMIs at school age
that were not significantly different between the groups.
Adequate nutrition is mandatory for preventing lung injury
and allowing lung growth in preterm infants, particularly
for those with BPD. Fifth, our good results probably
correspond to the improvements in lung function observed
at school age by others.
44
Atopy
There is some controversy concerning the association
between atopy, prematurity and BPD.
20,21,26-28,32
In our study, no evidence of an association between atopy
and BPD was found. Wheezing was observed in 61.5% of
the children with BPD and 71.9% of those without BPD
(Table II).
The prevalence of wheezing during infancy and early
childhood among VLBW infants is high. Siltanen et al. has
shown that preterm wheezers who still wheezed at age of 10
were atopic significantly more often than those who no
longer wheezed (62% vs. 9%, p=0.006). Although atopy is
not associated with a lifetime prevalence of respiratory
symptoms in prematurely born children, an atopic predis-
position has been found to be associated with the
persistence of wheezing.
20
In a previous study, we found that respiratory symptoms
were related to perinatal events (specifically, mechanical
ventilation and oxygen therapy) and not to the existence of
atopy.
32 These findings have not been confirmed by others;
they have found that that chronic and recurrent episodes of
wheezing are more directly related to atopy than to neonatal
problems.
28
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to respiratory symptoms at school age, as has previously
been reported.
21
Of the 19 patients with a family history of atopy, 6 (32%)
had positive skin-prick tests. Of 21 children with allergies,
15 (71%) had no familial history of atopy. These results are
not significantly different from those of the general
Portuguese population, in which the prevalence of asthma
at school age is approximately 10 to 12% and in which atopy




Our data show no significant differences in lung function
between BPD and no BPD patients at school age and no
evidence of an association between atopy and BPD.
In spite of greater morbidity in the early lives of children
with BDP, our data point to good respiratory outcomes at
school age, which is consistent with some studies that have
shown an improvement in lung function with age.
45 In this
very high-risk population, however, residual abnormalities
may persist later in life, which supports careful follow-up of
the clinical condition and lung function of these patients. The
importance of these respiratory problems in adult life needs
to be determined (whether BPD survivors have a greater risk
of developing a chronic obstructive pulmonary disease-like
phenotype with aging, for example). Only longitudinal lung
function studies will answer such questions.
Further studies need to be performed with extremely low
gestational age and extremely low birth weight infants
because this population has a high risk of lung function
impairment.
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